Clinical update on K-Ras targeted therapy in gastrointestinal cancers
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“research has focused on the inhibition of downstream effectors of KRAS oncoproteins in the MAPK pathway”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3747 · Cited by 368
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293
Inhibition of RAS function through targeting an allosteric regulatory site
Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R. R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2231 · Cited by 283
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0188 · Cited by 240
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236
Franco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Burns, M. C., Sun, Q., Daniels, R. N., Camper, D., Kennedy, J. P., Phan, J., Olejniczak, E. T., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315798111 · Cited by 199
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176
Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.66 · Cited by 166
Self-citationMolina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
Improving prospects for targeting RAS
Singh, H., Longo, D. L., & Chabner, B. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1052 · Cited by 107
K-Ras protein as a drug target
McCormick, F. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1382-7 · Cited by 105
Grilley-Olson, J. E., Bedard, P. L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A. R. A., Stayner, L.-A., Wu, Y., Greenwood, R., Singh, R., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0377-0 · Cited by 81
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76
Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H. M., Spano, J.-P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0341 · Cited by 71
Ramot, Y., Rotkopf, S., Gabai, R. M., Zorde Khvalevsky, E., Muravnik, S., Marzoli, G. A., Domb, A. J., Shemi, A., & Nyska, A. (2016) · Toxicologic Pathology · doi:10.1177/0192623316645860 · Cited by 64
Deming, D. A., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Eickhoff, J. C., Kolesar, J. M., Fioravanti, S., Greten, T. F., Compton, K., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-015-0314-7 · Cited by 52
Palmer, D. H., Dueland, S., Valle, J. W., & Aksnes, A.-K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4119 · Cited by 12
Research works printed but not linked: 125
- Abdul Razak, 2016, First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors, J. Clin. Oncol., 34, 4142, 10.1200/JCO.2015.65.3949 · DOI · Paper page
- Adair, 2012, Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients, Sci. Transl. Med., 4, 138ra77, 10.1126/scitranslmed.3003578 · DOI · Paper page
- Adjei, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers, J. Clin. Oncol., 26, 2139, 10.1200/JCO.2007.14.4956 · DOI · Paper page
- Akinleye, 2015, Novel agents for advanced pancreatic cancer, Oncotarget, 6, 39521, 10.18632/oncotarget.3999 · DOI
- Allegra, 2016, Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015, J. Clin. Oncol., 34, 179, 10.1200/JCO.2015.63.9674 · DOI · Paper page
- Andrews, 2013, BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition, J. Clin. Oncol., 31, e448, 10.1200/JCO.2013.50.4118 · DOI
- Athuluri-Divakar, 2016, A small molecule RAS-Mimetic disrupts RAS association with effector proteins to block signaling, Cell, 165, 643, 10.1016/j.cell.2016.03.045 · DOI · Paper page
- Bedard, 2015, A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors, Clin. Cancer Res., 21, 730, 10.1158/1078-0432.CCR-14-1814 · DOI · Paper page
- Bendell, 2011, Abstract B243: a phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors, Mol. Cancer Ther., 10, B243, 10.1158/1535-7163.TARG-11-B243 · DOI
- Bendell, 2018, A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC), J. Clin. Oncol., 36
- Benson, 2017, Colon Cancer, version 1.2017, NCCN clinical practice guidelines in oncology, J. Compr. Canc. Netw., 370, 10.6004/jnccn.2017.0036 · DOI · Paper page
- Blake, 2016, Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-y l)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development, J. Med. Chem., 59, 5650, 10.1021/acs.jmedchem.6b00389 · DOI · Paper page
- Bournet, 2016, Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: hopes and realities, Eur. J. Cancer, 54, 75, 10.1016/j.ejca.2015.11.012 · DOI · Paper page
- Brown, 2017, Maximising the potential of AKT inhibitors as anti-cancer treatments, Pharmacol. Ther., 172, 101, 10.1016/j.pharmthera.2016.12.001 · DOI · Paper page
- Buck, 2008, Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors, Cancer Res., 68, 8322, 10.1158/0008-5472.CAN-07-6720 · DOI · Paper page
- Callahan, 2012, Progression of RAS-mutant leukemia during RAF inhibitor treatment, N. Engl. J. Med., 367, 2316, 10.1056/NEJMoa1208958 · DOI · Paper page
- Carlino, 2015, New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma, J. Clin. Oncol., 33, e52, 10.1200/JCO.2013.51.5783 · DOI
- Casar, 2016, ERK Signals: Scaffolding Scaffolds?, Front. Cell Dev. Biol., 4, 49, 10.3389/fcell.2016.00049 · DOI
- Chu, 2016, Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells, Oncogene, 35, 3897, 10.1038/onc.2015.458 · DOI
- Coeshott, 2014, Abstract A28: immune responses to mutated Ras - development of a yeast-based immunotherapeutic, Mol. Cancer Res., 12, 10.1158/1557-3125.RASONC14-A28 · DOI
- Day, 2013, PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer, Clin. Cancer Res., 19, 3285, 10.1158/1078-0432.CCR-12-3614 · DOI · Paper page
- de la Chapelle, 2010, Clinical relevance of microsatellite instability in colorectal cancer, J. Clin. Oncol., 28, 3380, 10.1200/JCO.2009.27.0652 · DOI · Paper page
- De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol., 11, 753, 10.1016/S1470-2045(10)70130-3 · DOI · Paper page
- Delaney, 2017, Abstract 3015: selective inhibition of mutant KRAS cell and tumor growth by PHT-7.3, an inhibitor of the KRas signaling nanocluster protein Cnk1, Cancer Res., 77, 3015, 10.1158/1538-7445.AM2017-3015 · doi:10.1158/1538-7445.am2017-3015
- Delord, 2010, First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors, J. Clin. Oncol., 28, 10.1200/jco.2010.28.15_suppl.2504 · DOI
- Desai, 2016, Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors, Cancer Res., 76
- Desai, 2017, A phase IB study of RAF dimer inhibitor BGB -283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors, Cancer Res., 77
- Dhawan, 2016, Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling, Nature, 537, 112, 10.1038/nature19327 · DOI · Paper page
- Di Nicolantonio, 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus, J. Clin. Invest., 120, 2858, 10.1172/JCI37539 · DOI · Paper page
- Dickson, 2015, Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors, Invest. New Drugs, 33, 349, 10.1007/s10637-014-0191-5 · DOI
- Do, 2015, Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Invest. New Drugs, 33, 720, 10.1007/s10637-015-0212-z · DOI · Paper page
- Ducreux, 2015, Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 26, v56, 10.1093/annonc/mdv295 · DOI · Paper page
- Eriksen, 2017, An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer, Ann. Oncol., 28, 10.1093/annonc/mdx376.018 · DOI
- Etoh, 2003, Oncolytic viral therapy for human pancreatic cancer cells by reovirus, Clin. Cancer Res., 9, 1218
- Fernandez-Medarde, 2011, Ras in cancer and developmental diseases, Genes Cancer, 2, 344, 10.1177/1947601911411084 · DOI · Paper page
- Ganesan, 2013, Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations, Mol. Cancer Ther., 12, 2857, 10.1158/1535-7163.MCT-13-0319-T · DOI · Paper page
- Gonsalves, 2014, Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju106 · DOI · Paper page
- Graham, 2016, Molecular subtypes and personalized therapy in metastatic colorectal Cancer, Curr. Colorectal Cancer Rep., 12, 141, 10.1007/s11888-016-0312-y · DOI
- Harris, 2016, Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours, J. Clin. Oncol., 34, abstr 2582, 10.1200/JCO.2016.34.15_suppl.2582 · DOI
- Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 · DOI · Paper page
- Hayes, 2016, Long-term ERK inhibition in KRAS-Mutant pancreatic Cancer is associated with MYC degradation and senescence-like growth suppression, Cancer Cell, 29, 75, 10.1016/j.ccell.2015.11.011 · DOI · Paper page
- Heestand, 2015, Molecular landscape of pancreatic cancer: implications for current clinical trials, Oncotarget, 6, 4553, 10.18632/oncotarget.2972 · DOI
- Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 · DOI · Paper page
- Heist, 2014, Pimasertib (PIM) and SAR245409 (SAR) - a MEK and PI3K/MTOR inhibitor combination: a phase IB trial with expansions in selected genotype-defined solid tumors, Ann. Oncol., 25, iv146, 10.1093/annonc/mdu331.3 · DOI
- Herrero, 2015, Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes, Cancer Cell, 28, 170, 10.1016/j.ccell.2015.07.001 · DOI
- Hochster, 2015, Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer, Cancer Chemother. Pharmacol., 75, 17, 10.1007/s00280-014-2609-3 · DOI
- Hong, 2016, First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors, J. Clin. Oncol., 34, 2570, 10.1200/JCO.2016.34.15_suppl.2570 · doi:10.1200/jco.2016.34.15_suppl.2570
- Huang, 2009, Prognostic value of CRM1 in pancreas cancer, Clin. Invest. Med., 32, E315, 10.25011/cim.v32i6.10668 · DOI · Paper page
- Ihle, 2009, Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance, Cancer Res., 69, 143, 10.1158/0008-5472.CAN-07-6656 · DOI · Paper page
- Infante, 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas, Eur. J. Cancer, 50, 2072, 10.1016/j.ejca.2014.04.024 · DOI · Paper page
- Jameson, 2013, IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors, Nat. Med., 19, 626, 10.1038/nm.3165 · DOI · Paper page
- Janku, 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors, Mol. Cancer Ther., 10, 558, 10.1158/1535-7163.MCT-10-0994 · DOI · Paper page
- Janku, 2013, PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials, Cancer Res., 73, 276, 10.1158/0008-5472.CAN-12-1726 · DOI · Paper page
- Juric, 2014, A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors, J. Clin. Oncol., 32, 9051, 10.1200/jco.2014.32.15_suppl.9051 · DOI · Paper page
- Kamerkar, 2017, Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer, Nature, 546, 498, 10.1038/nature22341 · DOI · Paper page
- Kazim, 2015, Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic Cancer, Mol. Cancer Ther., 14, 1570, 10.1158/1535-7163.MCT-15-0104 · DOI
- Kim, 2013, Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer, Int. J. Cancer, 133, 984, 10.1002/ijc.28073 · DOI
- Kim, 2016, The inositide signaling pathway As a target for treating gastric Cancer and colorectal Cancer, Front. Physiol., 7, 168, 10.3389/fphys.2016.00168 · DOI
- Kimmelman, 2015, Metabolic dependencies in RAS-Driven cancers, Clin. Cancer Res., 21, 1828, 10.1158/1078-0432.CCR-14-2425 · DOI · Paper page
- Knickelbein, 2015, Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer, Genes Dis., 2, 4, 10.1016/j.gendis.2014.10.002 · DOI · Paper page
- Ko, 2016, A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma, Clin. Cancer Res., 22, 61, 10.1158/1078-0432.CCR-15-0979 · DOI · Paper page
- Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 · DOI · Paper page
- Lee, 2011, Identification and characterization of a novel integrin-linked kinase inhibitor, J. Med. Chem., 54, 6364, 10.1021/jm2007744 · DOI · Paper page
- Lievre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res., 66, 3992, 10.1158/0008-5472.CAN-06-0191 · DOI · Paper page
- Lim, 2016, Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers, J. Med. Chem., 59, 6501, 10.1021/acs.jmedchem.6b00708 · DOI
- Lin, 2016, The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors, Mol. Cell Oncol., 3, e1021441, 10.1080/23723556.2015.1021441 · DOI
- LoRusso, 2012, A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors, J. Clin. Oncol., 30, 2566, 10.1200/jco.2012.30.15_suppl.2566 · DOI · Paper page
- Macarulla, 2015, Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer, Br. J. Cancer, 112, 1874, 10.1038/bjc.2015.144 · DOI · Paper page
- Mahalingam, 2015, Oncolytic virus therapy in pancreatic cancer: clinical efficacy and pharmacodynamic analysis of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinom, Ann. Oncol., 26, iv51, 10.1093/annonc/mdv233.175 · doi:10.1093/annonc/mdv233.175
- Mahalingam, 2017, A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP), J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.e15753 · DOI
- Mann, 2016, KRAS-related proteins in pancreatic cancer, Pharmacol. Ther., 168, 29, 10.1016/j.pharmthera.2016.09.003 · DOI · Paper page
- Martinez-Garcia, 2012, First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors, Clin. Cancer Res., 18, 4806, 10.1158/1078-0432.CCR-12-0742 · DOI · Paper page
- Martin-Gago, 2017, Structure-based development of PDEdelta inhibitors, Biol. Chem., 398, 535, 10.1515/hsz-2016-0272 · DOI · Paper page
- Matsunaga, 2014, IQGAP1 selectively interacts with K-Ras but not with H-Ras and modulates K-Ras function, Biochem. Biophys. Res. Commun., 444, 360, 10.1016/j.bbrc.2014.01.041 · DOI
- McDonald, 2008, Integrin-linked kinase--essential roles in physiology and cancer biology, J. Cell. Sci., 121, 3121, 10.1242/jcs.017996 · DOI · Paper page
- Middleton, 2014, 364 first-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma, Eur. J. Cancer, 50, 117, 10.1016/S0959-8049(14)70490-3 · doi:10.1016/s0959-8049(14)70490-3
- Namgoong, 2016, A selective and potent pan-RAF inhibitor, HM95573 exhibits high therapeutic potential as a next-generation RAF inhibitor by direct inhibition of RAF kinase activity in BRAF or RAS mutant cancers, Eur. J. Cancer, 69, S127, 10.1016/S0959-8049(16)32979-3 · doi:10.1016/s0959-8049(16)32979-3
- Ning, 2017, Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer, Oncotarget, 8, 44295, 10.18632/oncotarget.17869 · DOI
- O’Neil, 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer, Ann. Oncol., 26, 1923, 10.1093/annonc/mdv264 · DOI
- Oberholzer, 2012, RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors, J. Clin. Oncol., 30, 316, 10.1200/JCO.2011.36.7680 · DOI · Paper page
- Ocean, 2013, A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC), J. Clin. Oncol., 31
- Ogino, 2009, PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer, J. Clin. Oncol., 27, 1477, 10.1200/JCO.2008.18.6544 · DOI · Paper page
- Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9 · DOI · Paper page
- Papke, 2016, Identification of pyrazolopyridazinones as PDEdelta inhibitors, Nat. Commun., 7, 11360, 10.1038/ncomms11360 · DOI · Paper page
- Parker, 2015, The ras-membrane interface: isoform-specific differences in the catalytic domain, Mol. Cancer Res., 13, 595, 10.1158/1541-7786.MCR-14-0535 · DOI · Paper page
- Pecot, 2014, Therapeutic silencing of KRAS using systemically delivered siRNAs, Mol. Cancer Ther., 13, 2876, 10.1158/1535-7163.MCT-14-0074 · DOI · Paper page
- Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 · DOI · Paper page
- Rajani, 2016, Combination therapy with reovirus and Anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses, Mol. Ther., 24, 166, 10.1038/mt.2015.156 · DOI · Paper page
- Rasco, 2013, MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: phase I study, J. Clin. Oncol., 31, 10.1200/jco.2013.31.15_suppl.2547 · doi:10.1200/jco.2013.31.15_suppl.2547
- Revenko, 2013, Characterization of next generation (Gen2.5) KRAS antisense inhibitors in NSCLC, PDAC, and CRC models, Mol. Cancer Ther., 12, A259, 10.1158/1535-7163.TARG-13-A259 · DOI
- Richards, 2012, A phase 2 adjuvant trial of GI-4000 plus gemcitabine vs. Gemcitabine alone in RAS+ patients with resected pancreas cancer: R1 subgroup analysis, Ann. Oncol., 23, iv5, 10.1016/S0923-7534(19)66467-7 · DOI
- Sahin, 2013, Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature, J. Cancer, 4, 320, 10.7150/jca.3619 · DOI · Paper page
- Sartore-Bianchi, 2016, Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory, Ann. Oncol., 27, 1456, 10.1093/annonc/mdw191 · DOI
- Sawai, 2006, Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival, Oncogene, 25, 3237, 10.1038/sj.onc.1209356 · DOI
- Seguin, 2017, Galectin-3, a druggable vulnerability for KRAS-Addicted cancers, Cancer Discov., 7, 1464, 10.1158/2159-8290.CD-17-0539 · DOI · Paper page
- Seow, 2016, Advances in targeted and immunobased therapies for colorectal cancer in the genomic era, Onco. Ther., 9, 1899, 10.2147/OTT.S95101 · DOI
- Shin, 2017, Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration, Nat. Commun., 8, 15090, 10.1038/ncomms15090 · DOI
- Singh, 2015, Immune checkpoints and immunotherapy for colorectal cancer, Gastroenterol. Rep. (Oxf)., 3, 289
- Smakman, 2005, Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D, J. Virol., 79, 14981, 10.1128/JVI.79.23.14981-14985.2005 · doi:10.1128/jvi.79.23.14981-14985.2005
- Smakman, 2006, Immunosuppression promotes reovirus therapy of colorectal liver metastases, Cancer Gene Ther., 13, 815, 10.1038/sj.cgt.7700949 · DOI
- Strand, 2016, Precision cancer therapy through nanoparticle delivery of siRNA against KRAS, J. Clin. Oncol., 34
- Strong, 1998, The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus, EMBO J., 17, 3351, 10.1093/emboj/17.12.3351 · DOI · Paper page
- Sullivan, 2018, First-in-Class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study, Cancer Discov., 8, 184, 10.1158/2159-8290.CD-17-1119 · DOI · Paper page
- Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 3, 406, 10.1158/2159-8290.CD-12-0429 · DOI · Paper page
- Tan, 2013, Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models, Mol. Cancer Ther., 12, 853, 10.1158/1535-7163.MCT-12-0949 · DOI · Paper page
- Tang, 2016, A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC), J. Clin. Oncol., 34
- Tape, 2016, Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation, Cell, 165, 910, 10.1016/j.cell.2016.03.029 · DOI · Paper page
- Thind, 2017, Immunotherapy in pancreatic cancer treatment: a new frontier, Therap. Adv. Gastroenterol., 10, 168, 10.1177/1756283X16667909 · DOI
- Tian, 2017, Development of direct inhibitors of KRAS mutants for the treatment of cancer, Cancer Res., 77, 3237, 10.1158/1538-7445.AM2017-3237 · DOI
- Tolcher, 2015, Antitumor activity in RAS-driven tumors by blocking AKT and MEK, Clin. Cancer Res., 21, 739, 10.1158/1078-0432.CCR-14-1901 · DOI · Paper page
- Tsang, 2017, U1 adaptors suppress the KRAS-MYC oncogenic Axis in human pancreatic Cancer xenografts, Mol. Cancer Ther., 16, 1445, 10.1158/1535-7163.MCT-16-0867 · DOI
- Turner, 2012, Nuclear export of proteins and drug resistance in cancer, Biochem. Pharmacol., 83, 1021, 10.1016/j.bcp.2011.12.016 · DOI · Paper page
- Vakana, 2017, LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer, Oncotarget, 8, 9251, 10.18632/oncotarget.14002 · DOI · Paper page
- Van Cutsem, 2018, Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer, Int. J. Cancer, 10.1002/ijc.31603 · DOI · Paper page
- Varga, 2016, A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors, Eur. J. Cancer, 69, S11, 10.1016/S0959-8049(16)32624-7 · DOI
- Weden, 2011, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras, Int. J. Cancer, 128, 1120, 10.1002/ijc.25449 · DOI · Paper page
- Weekes, 2017, A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors, Cancer Res., 77, CT107, 10.1158/1538-7445.AM2017-CT107 · DOI
- Welsch, 2017, Multivalent small-molecule Pan-RAS inhibitors, Cell, 168, 878, 10.1016/j.cell.2017.02.006 · DOI · Paper page
- Wilky, 2015, A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours, Br. J. Cancer, 112, 24, 10.1038/bjc.2014.515 · DOI
- Winter, 2015, Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation, J. Med. Chem., 58, 2265, 10.1021/jm501660t · DOI · Paper page
- Xing, 2003, Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer, Nat. Med., 9, 1266, 10.1038/nm927 · DOI
- Yu, 2015, The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy, Future Med. Chem., 7, 269, 10.4155/fmc.14.143 · DOI · Paper page
- Zhao, 2015, Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells, Oncotarget, 6, 14472, 10.18632/oncotarget.3991 · DOI
- Zhu, 2012, PI3K expression and PIK3CA mutations are related to colorectal cancer metastases, World J. Gastroenterol., 18, 3745, 10.3748/wjg.v18.i28.3745 · DOI · Paper page
- Ziemke, 2016, Sensitivity of KRAS-Mutant colorectal cancers to combination therapy that cotargets MEK and CDK4/6, Clin. Cancer Res., 22, 405, 10.1158/1078-0432.CCR-15-0829 · DOI · Paper page
Cited by
Vitiello, P. P., Cardone, C., Martini, G., Ciardiello, D., Belli, V., Matrone, N., Barra, G., Napolitano, S., Della Corte, C., Turano, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1035-0 · Cited by 96
Self-citationGiopanou, I., & Pintzas, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102859 · Cited by 17
Metadata
- Authors
- Pant, S., Hubbard, J., Martinelli, E., & Bekaii-Saab, T.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 130
- Pages
- 78-91
- ISSN
- 1040-8428
- Cited by
- 18
- References
- 47
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Senhwa Biosciences, Inc
- Boston Biomedical, Inc
- Genentech, Taiho Pharmaceuticals
- Merck. Dr. Hubbard
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.